Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 102 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,658 | -25.7% | 220 | 0.0% | 0.00% | 0.0% |
Q1 2024 | $3,577 | +138.5% | 220 | 0.0% | 0.00% | +100.0% |
Q4 2023 | $1,500 | +25.1% | 220 | 0.0% | 0.00% | 0.0% |
Q3 2023 | $1,199 | -19.7% | 220 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $1,494 | +35.6% | 220 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $1,102 | +2.6% | 220 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $1,074 | -89.3% | 220 | -69.4% | 0.00% | -88.9% |
Q3 2022 | $10,000 | -9.1% | 720 | 0.0% | 0.01% | 0.0% |
Q2 2022 | $11,000 | +22.2% | 720 | 0.0% | 0.01% | +50.0% |
Q1 2022 | $9,000 | -35.7% | 720 | -17.2% | 0.01% | -33.3% |
Q4 2021 | $14,000 | -54.8% | 870 | -21.1% | 0.01% | -60.9% |
Q3 2021 | $31,000 | -27.9% | 1,103 | -13.9% | 0.02% | -28.1% |
Q2 2021 | $43,000 | +290.9% | 1,281 | +265.0% | 0.03% | +255.6% |
Q1 2021 | $11,000 | -42.1% | 351 | -7.9% | 0.01% | -43.8% |
Q4 2020 | $19,000 | -78.4% | 381 | -83.3% | 0.02% | -79.7% |
Q3 2020 | $88,000 | +780.0% | 2,280 | +854.0% | 0.08% | +618.2% |
Q2 2020 | $10,000 | – | 239 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $2,757,000 | 9.37% |
Sofinnova Investments, Inc. | 2,194,278 | $31,641,000 | 1.84% |
MPM BioImpact LLC | 443,702 | $6,398,000 | 1.52% |
Artal Group S.A. | 400,000 | $5,768,000 | 0.25% |
Polar Capital Holdings Plc | 2,531,546 | $36,505,000 | 0.23% |
ASHFORD CAPITAL MANAGEMENT INC | 101,970 | $1,470,000 | 0.22% |
Lombard Odier Asset Management (Switzerland) SA | 168,795 | $2,434,000 | 0.21% |
Soleus Capital Management, L.P. | 87,182 | $1,257,000 | 0.17% |
Cormorant Asset Management, LP | 150,000 | $2,163,000 | 0.15% |
Walleye Capital LLC | 437,344 | $6,307,000 | 0.12% |